These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 26198719)

  • 21. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
    Hong SI; Ryu BH; Chong YP; Lee S; Kim S; Kim HC; Hong KW; Bae IG; Cho OH
    Int J Antimicrob Agents; 2020 Aug; 56(2):106052. PubMed ID: 32544570
    [No Abstract]   [Full Text] [Related]  

  • 22. Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection.
    Channappanavar R; Lu L; Xia S; Du L; Meyerholz DK; Perlman S; Jiang S
    J Infect Dis; 2015 Dec; 212(12):1894-903. PubMed ID: 26164863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection.
    Zhao J; Perera RA; Kayali G; Meyerholz D; Perlman S; Peiris M
    J Virol; 2015 Jun; 89(11):6117-20. PubMed ID: 25787284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
    Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
    Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
    [No Abstract]   [Full Text] [Related]  

  • 25. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.
    Chan JF; Chan KH; Kao RY; To KK; Zheng BJ; Li CP; Li PT; Dai J; Mok FK; Chen H; Hayden FG; Yuen KY
    J Infect; 2013 Dec; 67(6):606-16. PubMed ID: 24096239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.
    Hui DS; Memish ZA; Zumla A
    Curr Opin Pulm Med; 2014 May; 20(3):233-41. PubMed ID: 24626235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
    Kang CK; Seong MW; Choi SJ; Kim TS; Choe PG; Song SH; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2020 Jul; 35(4):782-787. PubMed ID: 32460458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.
    Khalid M; Al Rabiah F; Khan B; Al Mobeireek A; Butt TS; Al Mutairy E
    Antivir Ther; 2015; 20(1):87-91. PubMed ID: 24831606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
    Al-Tawfiq JA; Memish ZA
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):269-275. PubMed ID: 27937060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus.
    Iwata-Yoshikawa N; Okamura T; Shimizu Y; Kotani O; Sato H; Sekimukai H; Fukushi S; Suzuki T; Sato Y; Takeda M; Tashiro M; Hasegawa H; Nagata N
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
    Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
    Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lopinavir-ritonavir for COVID-19: A living systematic review.
    Verdugo-Paiva F; Izcovich A; Ragusa M; Rada G
    Medwave; 2020 Jul; 20(6):e7967. PubMed ID: 32678815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
    Chen Z; Bao L; Chen C; Zou T; Xue Y; Li F; Lv Q; Gu S; Gao X; Cui S; Wang J; Qin C; Jin Q
    J Infect Dis; 2017 Jun; 215(12):1807-1815. PubMed ID: 28472421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets.
    van Doremalen N; Falzarano D; Ying T; de Wit E; Bushmaker T; Feldmann F; Okumura A; Wang Y; Scott DP; Hanley PW; Feldmann H; Dimitrov DS; Munster VJ
    Antiviral Res; 2017 Jul; 143():30-37. PubMed ID: 28389142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease.
    Johnson RF; Via LE; Kumar MR; Cornish JP; Yellayi S; Huzella L; Postnikova E; Oberlander N; Bartos C; Ork BL; Mazur S; Allan C; Holbrook MR; Solomon J; Johnson JC; Pickel J; Hensley LE; Jahrling PB
    Virology; 2015 Nov; 485():422-30. PubMed ID: 26342468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does lopinavir measure up in the treatment of COVID-19?
    Doggrell SA
    Expert Opin Investig Drugs; 2020 Aug; 29(8):793-796. PubMed ID: 32475183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
    Park SY; Lee JS; Son JS; Ko JH; Peck KR; Jung Y; Woo HJ; Joo YS; Eom JS; Shi H
    J Hosp Infect; 2019 Jan; 101(1):42-46. PubMed ID: 30240813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MERS-CoV spike protein: a key target for antivirals.
    Du L; Yang Y; Zhou Y; Lu L; Li F; Jiang S
    Expert Opin Ther Targets; 2017 Feb; 21(2):131-143. PubMed ID: 27936982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.
    Chan JF; Lau SK; To KK; Cheng VC; Woo PC; Yuen KY
    Clin Microbiol Rev; 2015 Apr; 28(2):465-522. PubMed ID: 25810418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.